AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35652770 — intervention group
Group type: COMPARATOR
Intervention: Quincke needle
Number of subjects: 201
Study 32976576 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide 0.5 mg per day orally
Number of subjects: 34
Study 32976576 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide 2 mg per day (starting at 0.5 mg per day increasing to 2 mg per day over 6 weeks)
Number of subjects: 34
Study 32976576 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide (both doses)
Number of subjects: 34
Study 32976576 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide (high-dose cohort)
Number of subjects: 34
Study 32976576 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide (low-dose cohort)
Number of subjects: 34
Study 32538880 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT) plus multidisciplinary physical therapy protocol (MIRT)
Number of subjects: 24
Study 32538880 — intervention group
Group type: COMPARATOR
Intervention: Sham OMT plus multidisciplinary physical therapy protocol (MIRT)
Number of subjects: 24
Study 35108451 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline treatment
Number of subjects: 22
Study 35108451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 33050321 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity Diet (APAD) education program
Number of subjects: 360
Study 33050321 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 360
Study 32739897 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 0
Study 32739897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35382883 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily
Number of subjects: 0
Study 35382883 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 0
Study 35382883 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (active control)
Number of subjects: 0
Study 35382883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32205070 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacy-based intervention (PAcHA program)
Number of subjects: 0
Study 33186898 — intervention group
Group type: EXPERIMENTAL
Intervention: New Zealand blackcurrant extract 600 mg/day
Number of subjects: 13
Study 33186898 — intervention group
Group type: EXPERIMENTAL
Intervention: New Zealand blackcurrant extract 300 mg/day
Number of subjects: 13
Study 33186898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 33084477 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity program for 3 months
Number of subjects: 48
Study 33084477 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study 35012380 — intervention group
Group type: EXPERIMENTAL
Intervention: High Sense of Embodiment (SoE) condition
Number of subjects: 77
Study 35012380 — intervention group
Group type: COMPARATOR
Intervention: Low Sense of Embodiment (SoE) condition
Number of subjects: 77
Study 35012380 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin-ideal avatars exposure
Number of subjects: 77
Study 35012380 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit measures
Number of subjects: 77
Study 32910362 — intervention group
Group type: EXPERIMENTAL
Intervention: Infra-orbital first 3-point reduction and fixation (group B)
Number of subjects: 40
Study 32910362 — intervention group
Group type: COMPARATOR
Intervention: Frontozygomatic first 3-point reduction and fixation (group A)
Number of subjects: 40
Study 36229596 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine
Number of subjects: 107
Study 36229596 — intervention group
Group type: EXPERIMENTAL
Intervention: lithium
Number of subjects: 107
Study 34400480 — intervention group
Group type: EXPERIMENTAL
Intervention: RocketAP (fully automated closed-loop control system)
Number of subjects: 18
Study 32725102 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 34
Study 32725102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 36217496 — intervention group
Group type: EXPERIMENTAL
Intervention: NK105
Number of subjects: 123
Study 36217496 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (PTX)
Number of subjects: 123
Study 34578984 — intervention group
Group type: COMPARATOR
Intervention: Weight loss intervention
Number of subjects: 0
Study 34578984 — intervention group
Group type: COMPARATOR
Intervention: Combined exercise and weight loss intervention
Number of subjects: 0
Study 34578984 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss of ≥10%
Number of subjects: 0
Study 34578984 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of exercise and weight loss
Number of subjects: 0
Study 33382224 — intervention group
Group type: EXPERIMENTAL
Intervention: PC+ERAS
Number of subjects: 300
Study 33382224 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care (Control)
Number of subjects: 300
Study 34990281 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-driven arm after 2 × BEACOPP delivering 4 × ABVD in PET2- and 4 × BEACOPP in PET2+ patients.
Number of subjects: 823
Study 34990281 — intervention group
Group type: COMPARATOR
Intervention: Standard arm (6 × BEACOPP).
Number of subjects: 823
Study 34990281 — intervention group
Group type: EXPERIMENTAL
Intervention: Full interim PET assessment.
Number of subjects: 823
Study 34990281 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim PET results.
Number of subjects: 823
Study 34990281 — intervention group
Group type: EXPERIMENTAL
Intervention: Second primary malignancy incidence.
Number of subjects: 823
Study 33771940 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional clothing (standardized training ensemble plus compression garments and full tracksuit)
Number of subjects: 14
Study 33771940 — intervention group
Group type: COMPARATOR
Intervention: Control (synthetic rugby shorts and training tee)
Number of subjects: 14
Study 32495631 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 0
Study 32495631 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombocytopenia
Number of subjects: 0
Study 32495631 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukopenia
Number of subjects: 0
Study 32495631 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutropenia
Number of subjects: 0
Study 32495631 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphopenia
Number of subjects: 0
Study 32495631 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancytopenia
Number of subjects: 0
Study 35238296 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh plate (Super Fixorb MX40®; Takiron Co. Ltd., Osaka, Japan)
Number of subjects: 70
Study 35238296 — intervention group
Group type: COMPARATOR
Intervention: Wire cerclage
Number of subjects: 70
Study 32892605 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopy-guided thoracic paravertebral block with 0.375% ropivacaine (20 ml) at thoracic 4-5 intercostal
Number of subjects: 60
Study 32892605 — intervention group
Group type: COMPARATOR
Intervention: Patient controlled intravenous analgesia (PCIA)
Number of subjects: 60
Study 32892605 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopy-guided thoracic paravertebral block
Number of subjects: 60
Study 35961761 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab (75/150 mg based on weight)
Number of subjects: 86
Study 35961761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 34391310 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy alone (Group 1)
Number of subjects: 65
Study 34391310 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy (3 J/cm²) plus drug therapy (Group 2)
Number of subjects: 65
Study 34391310 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy (6 J/cm²) plus drug therapy (Group 3)
Number of subjects: 65
Study 34391310 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy plus placebo laser therapy (Group 4)
Number of subjects: 65
Study 32436683 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 mcg
Number of subjects: 10355
Study 32436683 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate/vilanterol (FF/VI) 100/25 mcg
Number of subjects: 10355
Study 32436683 — intervention group
Group type: COMPARATOR
Intervention: Umeclidinium/vilanterol (UMEC/VI) 62.5/25 mcg
Number of subjects: 10355
Study 32436683 — intervention group
Group type: COMPARATOR
Intervention: Comparison of FF/UMEC/VI with FF/VI
Number of subjects: 10355
Study 32436683 — intervention group
Group type: COMPARATOR
Intervention: Comparison of FF/UMEC/VI with UMEC/VI
Number of subjects: 10355
Study 36229116 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral rehearsal (simulated role-plays; n = 43)
Number of subjects: 126
Study 36229116 — intervention group
Group type: COMPARATOR
Intervention: Self-report (n = 41)
Number of subjects: 126
Study 36229116 — intervention group
Group type: COMPARATOR
Intervention: Chart-stimulated recall (semistructured interviews with the chart available; n = 42)
Number of subjects: 126
Study 34616111 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin-rich onion (daily quercetin intake, 50 mg as aglycone equivalent)
Number of subjects: 70
Study 34616111 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin-rich onion
Number of subjects: 70
Study 34616111 — intervention group
Group type: COMPARATOR
Intervention: Quercetin-free onion (placebo)
Number of subjects: 70
Study 35124347 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic lens
Number of subjects: 67
Study 35124347 — intervention group
Group type: COMPARATOR
Intervention: No acoustic lens (control)
Number of subjects: 67
Study 34621937 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency (HF) surveillance regimen: cystoscopy every 3 months for 2 years, then every 6 months for 2 years, then annually.
Number of subjects: 70
Study 34621937 — intervention group
Group type: COMPARATOR
Intervention: Low frequency (LF) surveillance regimen: cystoscopy at 9 months following the 3-month cystoscopy, then annually.
Number of subjects: 70
Study 34621937 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency (HF) surveillance regimen
Number of subjects: 70
Study 34621937 — intervention group
Group type: COMPARATOR
Intervention: Low frequency (LF) surveillance regimen
Number of subjects: 70
Study 34621937 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 34252301 — intervention group
Group type: COMPARATOR
Intervention: Ravidasvir (RDV) 200 mg alone on day 1
Number of subjects: 0
Study 34252301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravidasvir (RDV) 200 mg plus Danoprevir/Ritonavir (DNVr) 100 mg/100 mg twice daily for 10 days
Number of subjects: 0
Study 34252301 — intervention group
Group type: COMPARATOR
Intervention: Danoprevir/Ritonavir (DNVr) 100 mg/100 mg twice daily
Number of subjects: 0
Study 34252301 — intervention group
Group type: COMPARATOR
Intervention: Ravidasvir (RDV) single doses of 100, 200, and 300 mg
Number of subjects: 0
Study 34252301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravidasvir (RDV) with or without DNVr
Number of subjects: 0
Study 35532326 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely-delivered cancer-specific exercise education video
Number of subjects: 364
Study 35532326 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education video)
Number of subjects: 364
Study 33296898 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (IUSim™ simulator)
Number of subjects: 6
Study 33296898 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6
Study 33296898 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 6
Study 32393215 — intervention group
Group type: EXPERIMENTAL
Intervention: Revefenacin 175 μg
Number of subjects: 0
Study 32393215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35908570 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg once daily
Number of subjects: 314
Study 35908570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 32535600 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO + pharmacological treatment (HBO+P)
Number of subjects: 136
Study 32535600 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment (P)
Number of subjects: 136
Study 32828994 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary lip surgery
Number of subjects: 80
Study 32828994 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers with bilateral CLP infants
Number of subjects: 80
Study 32828994 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents with local anesthesia experience
Number of subjects: 80
Study 32828994 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age
Number of subjects: 80
Study 32828994 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal age
Number of subjects: 80
Study 36066123 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200 or 300mg every 2 weeks
Number of subjects: 530
Study 36066123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study 32895918 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-sleep duration
Number of subjects: 367586
Study 32895918 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-sleep duration
Number of subjects: 367586
Study 32350931 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based minimally supervised exercise program (exercise on a stationary cycle and strengthening of upper limbs; stretching of the hands)
Number of subjects: 44
Study 32350931 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 44
Study 32350931 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based minimally supervised exercise program
Number of subjects: 44
Study 35522281 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month web-based group-coaching program (Better Together Physician Coaching)
Number of subjects: 101
Study 35522281 — intervention group
Group type: COMPARATOR
Intervention: Control group (residency training as usual)
Number of subjects: 101
Study 33861329 — intervention group
Group type: EXPERIMENTAL
Intervention: Loving-kindness meditation (n = 91); 12 weekly 90-minute group sessions.
Number of subjects: 184
Study 33861329 — intervention group
Group type: COMPARATOR
Intervention: Cognitive processing therapy (n = 93); 12 weekly 90-minute group sessions.
Number of subjects: 184
Study 35307465 — intervention group
Group type: EXPERIMENTAL
Intervention: ADD group (pecans 68 g)
Number of subjects: 16
Study 35307465 — intervention group
Group type: COMPARATOR
Intervention: Control group (nut-free)
Number of subjects: 16
Study 34732491 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine treatment (60 mg/day for 7 weeks)
Number of subjects: 111
Study 34732491 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no additional treatment)
Number of subjects: 111
Study 34287493 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment and adjuvant laser therapy
Number of subjects: 38
Study 34287493 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 38
Study 32739310 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation program (4-week supervised preoperative exercise training)
Number of subjects: 54
Study 32739310 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation program
Number of subjects: 54
Study 36215044 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) with medical therapy
Number of subjects: 202
Study 36215044 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 202
Study 33529266 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 publications (76 total)
Number of subjects: 402
Study 33529266 — intervention group
Group type: COMPARATOR
Intervention: Non-COVID publications (154 in 2020, 172 in 2019)
Number of subjects: 402
Study 33529266 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 publications
Number of subjects: 402
Study 35687757 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutimlimab
Number of subjects: 42
Study 35687757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 32964565 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 34
Study 32964565 — intervention group
Group type: EXPERIMENTAL
Intervention: SCIG
Number of subjects: 34
Study 32964565 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG and SCIG
Number of subjects: 34
Study 32329184 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 15
Study 32329184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 36159280 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram developed using training group data; validated in validation group.
Number of subjects: 2716
Study 36159280 — intervention group
Group type: COMPARATOR
Intervention: High-risk group based on nomogram predictions.
Number of subjects: 2716
Study 36159280 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram predictive performance in training group.
Number of subjects: 2716
Study 36159280 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram predictive performance in validation group.
Number of subjects: 2716
Study 36159280 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration slopes of nomogram in training and validation groups.
Number of subjects: 2716
Study 33874803 — intervention group
Group type: EXPERIMENTAL
Intervention: Full bandwidth direct drive hearing aids
Number of subjects: 15
Study 33874803 — intervention group
Group type: COMPARATOR
Intervention: Narrow bandwidth direct drive hearing aids
Number of subjects: 15
Study 32292093 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Number of subjects: 0
Study 32292093 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 0
Study 33010473 — intervention group
Group type: EXPERIMENTAL
Intervention: ETC + Patient Navigation (up to 10 h of navigation over a 3-month period)
Number of subjects: 44
Study 33010473 — intervention group
Group type: COMPARATOR
Intervention: ETC (list of smoking cessation resources)
Number of subjects: 44
Study 33010473 — intervention group
Group type: EXPERIMENTAL
Intervention: ETC + Patient Navigation
Number of subjects: 44
Study 36356037 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 IU vitamin D3 + 500 mg calcium
Number of subjects: 106
Study 36356037 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 IU vitamin D3 + 500 mg calcium
Number of subjects: 106
Study 36356037 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU vitamin D3 + 500 mg calcium
Number of subjects: 106
Study 36356037 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mg calcium)
Number of subjects: 106
Study 32640854 — intervention group
Group type: EXPERIMENTAL
Intervention: Active iTBS
Number of subjects: 39
Study 32640854 — intervention group
Group type: COMPARATOR
Intervention: Sham iTBS
Number of subjects: 39
Study 32772268 — intervention group
Group type: EXPERIMENTAL
Intervention: PICSI
Number of subjects: 413
Study 32772268 — intervention group
Group type: COMPARATOR
Intervention: MACS
Number of subjects: 413
Study 32772268 — intervention group
Group type: EXPERIMENTAL
Intervention: MACS (females < 30 years)
Number of subjects: 413
Study 32772268 — intervention group
Group type: EXPERIMENTAL
Intervention: PICSI (females 30-35 years)
Number of subjects: 413
Study 36481988 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation orally starting from 14 weeks gestation
Number of subjects: 100
Study 36481988 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 100
Study 36435474 — intervention group
Group type: EXPERIMENTAL
Intervention: Gummy candy enriched with 250 mg of Konjac glucomannan (KGM)
Number of subjects: 42
Study 36435474 — intervention group
Group type: COMPARATOR
Intervention: Placebo candy with 250 mg of flaxseed meal
Number of subjects: 42
Study 33471404 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Self-Compassion program (MSC)
Number of subjects: 123
Study 33471404 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioural Therapy (CBT)
Number of subjects: 123
Study 32555029 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 60
Study 32555029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 34656873 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 350
Study 34656873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 32791881 — intervention group
Group type: EXPERIMENTAL
Intervention: Early specialist palliative care (SPC)
Number of subjects: 174
Study 32791881 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 174
Study 34132492 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 7020
Study 34132492 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 7020
Study 34132492 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (pooled doses)
Number of subjects: 7020
Study 34132492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020
Study 33143203 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient fortified meal (570 kcal) in the form of a bar and shake containing >75% of the FDA Daily Values for all essential vitamins and minerals
Number of subjects: 35
Study 33143203 — intervention group
Group type: COMPARATOR
Intervention: Control meal (usual meal provided)
Number of subjects: 35
Study 33716963 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 15
Study 33716963 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 15
Study 32207718 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeomin (up to 800 U)
Number of subjects: 96
Study 32207718 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of xeomin and baclofen (10 mg 3 times a day)
Number of subjects: 96
Study 32207718 — intervention group
Group type: COMPARATOR
Intervention: Xeomin (monotherapy)
Number of subjects: 96
Study 35618380 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired coaching
Number of subjects: 252